An interventional study of Magnesium sulphate and Furosemide in Cisplatin-induced Nephrotoxicity, sponsored by Grigore T. Popa University of Medicine and Pharmacy. Completed at 1 site in Romania. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Grigore T. Popa University of Medicine and Pharmacy · Not applicable, Interventional, and Prevention
This prospective, randomized, open-label study evaluated whether intravenous magnesium sulphate added to standard hydration could reduce cisplatin-associated renal toxicity in adult patients with solid tumors receiving weekly cisplatin-based chemoradiotherapy. Participants were assigned to standard hydration with intravenous saline and furosemide or to the same hydration protocol supplemented with 1 g of intravenous magnesium sulphate before cisplatin administration. The primary outcome was early renal toxicity assessed 48 hours after cisplatin administration. Secondary outcomes included renal dysfunction at one year, changes in urinary kidney injury biomarkers (KIM-1, NGAL, and suPAR), hematological toxicity, and treatment response
Grigore T. Popa University of Medicine and Pharmacy is the lead sponsor of 32 studies on the registry; 9 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants received 1 L of 0.9% sodium chloride solution with 20 mg of intravenous furosemide over 1 hour before cisplatin administration, followed by 1 L of 0.9% sodium chloride solution over 2 hours after cisplatin
Drug: Furosemide · Drug: Saline (0.9% NaCl)
Participants received 1 L of 0.9% sodium chloride solution with 1 g of intravenous magnesium sulphate and 20 mg of intravenous furosemide over 1 hour before cisplatin administration, followed by 1 L of 0.9% sodium chloride solution over 2 hours after cisplatin. Oral magnesium supplementation of 250-500 mg/day was recommended between chemotherapy cycles when serum magnesium was below 1.8 mg/dL before a subsequent cycle. Pasted text La Interventions, aș crea:
Drug: Magnesium sulphate · Drug: Furosemide · Drug: Saline (0.9% NaCl)
1 g intravenously before cisplatin administration, administered with the pre-hydration regimen.
20 mg intravenously before cisplatin administration as part of the hydration protocol.
1 L of 0.9% sodium chloride before cisplatin and 1 L after cisplatin.
Incidence of Early Cisplatin-Associated Renal Toxicity
Time frame: 48 hours after the first cisplatin administration (Day 3)
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Magnesium Sulfate
Grigore T. Popa University of Medicine and Pharmacy